LIVE WEBINAR: Wednesday, April 17, 2024 | 5:00 PM – 6:00 PM Eastern Time (ET)

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Oncology

A Multitumor CME/MOC-Accredited Live Webinar Series

Acute Myeloid Leukemia

Join us on Wednesday, April 17th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Naval Daver, MD
Director, Leukemia Research Alliance Program
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Courtney D DiNardo, MD, MSCE
Professor, Department of Leukemia
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Neil Love, MD
Research To Practice
Miami, Florida

This activity is supported by educational grants from AbbVie Inc, Astellas, Daiichi Sankyo Inc, Syndax Pharmaceuticals, and Taiho Oncology Inc.

Wednesday, April 17, 2024
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

  • PART I: Current and Emerging Role of Biomarker-Directed Therapeutic Approaches in the Care of Patients with Acute Myeloid Leukemia (AML)
  • PART II: Available and Emerging Nontargeted Therapies for AML

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of acute myeloid leukemia.

Learning Objectives
At the conclusion of this activity, participants should be able to

  • Recall emerging research data affecting the clinical management of various forms of acute myeloid leukemia (AML), and where applicable, adapt current treatment algorithms based on these findings.
  • Describe the biological rationale for and available research findings with Bcl-2-targeted therapy for patients with AML, and appraise the current and future role of this strategy in clinical care.
  • Reflect on available research evidence with approved FLT3 inhibitors, and use this information to appropriately guide the clinical care of patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
  • Develop an understanding of published data with and the current role of available IDH1/2 inhibitors in the care of patients with newly diagnosed or relapsed/refractory AML and an IDH1 or IDH2 mutation, and incorporate these agents into current disease management algorithms.
  • Recognize the scientific justification for the development of menin inhibitors for the treatment of certain genetically defined subsets of AML, and consider available research findings with these novel agents and their potential role in clinical practice.
  • Recollect the mechanisms of action of, available data with and ongoing studies evaluating novel agents and approaches for patients with AML, and provide appropriate counsel about the potential benefits of clinical trial participation.

CE Credit
CME and ABIM MOC credit links will be emailed to each participant within 3 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr DaverConsulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Arog Pharmaceuticals Inc, Astellas, Bristol Myers Squibb, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, ImmunoGen Inc, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Menarini Group, Novartis, Pfizer Inc, Servier Pharmaceuticals LLC, Shattuck Labs, Stemline Therapeutics Inc, Syndax Pharmaceuticals Inc, Trillium Therapeutics Inc; Contracted Research: AbbVie Inc, Amgen Inc, Astellas, Bristol Myers Squibb, Daiichi Sankyo Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlycoMimetics Inc, Hanmi Pharmaceutical, ImmunoGen Inc, Kite, A Gilead Company, NovImmune SA, Pfizer Inc, Servier Pharmaceuticals LLC, Trillium Therapeutics Inc, Trovagene. Dr DiNardoConsulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, GSK, Jazz Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, Schrödinger, Servier Pharmaceuticals LLC; Contracted Research: AbbVie Inc, Bristol Myers Squibb, Foghorn Therapeutics, Immune-Onc Therapeutics Inc, Rigel Pharmaceuticals Inc, Schrödinger, Servier Pharmaceuticals LLC; Data and Safety Monitoring Board/Committee: Genmab US Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AbbVie Inc, Astellas, Daiichi Sankyo Inc, Syndax Pharmaceuticals, and Taiho Oncology Inc.